News

Capital Market on MSN6d
AstraZeneca Pharma receives marketing approval for Benralizumab in India
AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of ...
Capital Market on MSN6d
AstraZeneca Pharma gets CDSCO nod to import and distribute for Benralizumab solution in India
Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory ...
Business Standard6d
AstraZeneca Pharma receives marketing approval for Benralizumab in India
AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution ...
pharmaphorum4d
EU clears AstraZeneca's new-form severe asthma drug Tezspire
AstraZeneca's first-in-class severe asthma ... and AZ's IL-5 inhibitor Fasenra (benralizumab) - which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's Cinqaero (reslizumab), which ...
Business Standard6d
AstraZeneca Pharma gets CDSCO nod to import and distribute for Benralizumab solution in India
AstraZeneca Pharma India announced that it has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import, ...
pharmaphorum2d
AstraZeneca gets first okay for CTLA4 drug tremelimumab
AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.